SCHEMBL3011644

SCHEMBL3011644

COc1ccccc1Cc1csc(N2CCC(S(=O)(=O)c3cc(Cl)cc(Cl)c3)CC2)n1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.36
MEN1 O00255 2/20 0.35
KMT2A Q03164 2/20 0.35
HTT P42858 2/20 0.35
NPSR1 Q6W5P4 1/20 0.35
KCNH2 Q12809 2/20 0.35
SCN9A Q15858 1/20 0.35
ALDH1A1 P00352 2/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
KDM4E B2RXH2 1/20 0.34
AR P10275 1/20 0.34
KDM1A O60341 1/20 0.34
CMA1 P23946 1/20 0.34
HTR7 P34969 1/20 0.34
HSD17B10 Q99714 1/20 0.34
HTR6 P50406 1/20 0.34
THRB P10828 1/20 0.34
DRD2 P14416 1/20 0.34
HTR2A P28223 1/20 0.34
HTR2C P28335 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3007560 0.94 KDM1A (0.40) MAPTMEN1KMT2AHTTKCNH2
SCHEMBL3006479 0.94 MAPT (0.40) MAPTMEN1KMT2AHTTNPSR1
SCHEMBL3018670 0.90 KCNA5 (0.38) MAPTMEN1KMT2AHTTNPSR1
SCHEMBL3015482 0.90 DRD2 (0.38) MAPTMEN1KMT2AHTTKCNH2
SCHEMBL3020144 0.89 RAB9A (0.38) MAPTMEN1KMT2ANPSR1ALDH1A1
SCHEMBL3018934 0.89 DRD2 (0.40) MAPTKMT2AHTTALDH1A1L3MBTL1
SCHEMBL3011725 0.89 MAPT (0.38) MAPTMEN1KMT2ANPSR1KCNH2
SCHEMBL3019256 0.89 TSHR (0.39) MAPTHTTALDH1A1L3MBTL1KDM4E
SCHEMBL3002832 0.89 TP53 (0.38) MAPTMEN1KMT2AHTTALDH1A1
SCHEMBL3012653 0.89 MEN1 (0.37) MAPTMEN1KMT2AALDH1A1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA MAPT 18/4885MEN1 454/4885KMT2A 2680/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.